Speakers included...

• 

  Dr Yoshiya OdaPresident, Biomarkers and Personalized Medicine Eisai

• 

  Dr Vijay ModurHead, Diagnostic Discovery Novartis

• 

  Jeffrey FillDirector, Clinical Diagnostics Laboratory Eli Lilly

• 

  Dr Donald ChalfinMedical Director, Health Economics and Outcomes Research Abbott

• 

  Dr Troy BrennanChief Medical Officer CVS Caremark

• 

  Rick SchatzbergCo-Founder, President and CEO Generation Health

• 

  Finley AustinPersonalized Healthcare & Biomarker Strategy Directory AstraZeneca

• 

  Dr Ian TaylorSenior Director, Translational Oncology Pfizer

World Companion Diagnostics Summit returns to Boston

The must-attend forum for drug and diagnostic developers returned to Boston at the end of November 2011. The World Companion Diagnostics Summit was designed by leading biomarker and companion diagnostics specialists at Roche, Novartis, Johnson & Johnson, GSK, Merck, AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer and many more to assist you in turning biomarker research into successful patient stratification and to deliver better, safer drugs to market with drug-diagnostic co-development.

With all the fascinating feedback we heard from you, we put together an agenda in 2012 that was packed with fresh, new insights and that addressed the most up-to-date issues and challenges in drug-diagnostic co-development.

So what was on the agenda?

The World Companion Diagnostics Summit was the perfect place to meet drug industry leaders and pioneering researchers to learn the latest approaches for stratifying patient populations with companion diagnostics and how to deliver better, safer drugs to market with this approach. Here are just some of the topics our experts addressed:

• Where are we now with the development, approval and commercialization of companion diagnostics? What are the different patient stratification strategies companies are taking, both in large pharma and smaller drug developing companies?
• How do you successfully translate treatment stratification markers from bench to bedside and move from a research grade assay towards a clinically useful diagnostic test?
• How do you take a biomarker test from clinical validation to commercialization?
• Should you invest in in-house development or outsource? Should you develop LDTs or IVDs? What are the benefits and challenges associated with both prospective and retrospective biomarker development and in defining biomarker positive and negative patient populations?
• Understand the latest FDA guidance and its impact on your research and development of stratified medicines
• What does the reimbursement landscape of companion diagnostics look like and how do you achieve a positive reimbursement decision?
• How do we articulate the value of companion diagnostics to the wider healthcare community and drive adoption?

Why attend next year?

Every presentation and contact will help you improve your research and business aims – everyone at the meeting is here to discuss how to achieve patient stratification and the targeting of drugs to specific patient populations by turning predictive biomarkers into robust diagnostic tests. 

Don’t just listen to speakers and attendees – meet them and discuss your work in our intimate and informal conference setting. Plus, we’ll make sure you meet and introduce yourself to everybody at the meeting in our dedicated speed networking session on the morning of day one. 

Receive tailored guidance on achieving patient stratification - our pre-conference workshops are a fantastic opportunity to get the information and contacts you need to achieve your research and business aims (over and above the inside information you will gain from the meeting itself).

Who's this meeting for?

Whether you are new to the field or expanding your existing capabilities around biomarker development and companion diagnostics, this meeting is a one-stop shop of the latest developments and strategies you need to be aware of. That means everyone involved with:

• Biomarkers (Companion) diagnostics 
• Personalized medicine  
• Portfolio and project management/strategy 
• Commercial/business development  
• Reimbursement/market access/health economic outcomes 
• Molecular profiling 
• Translational medicine  
• Pharmacogenomics/pharmacogenetics  
• Clinical development 
• Regulatory affairs